OrganoClick Inkomsten in het verleden
Verleden criteriumcontroles 0/6
OrganoClick's earnings have been declining at an average annual rate of -5%, while the Chemicals industry saw earnings growing at 7.9% annually. Revenues have been growing at an average rate of 11.4% per year.
Belangrijke informatie
-5.0%
Groei van de winst
-1.2%
Groei van de winst per aandeel
| Chemicals Groei van de industrie | 32.9% |
| Inkomstengroei | 11.4% |
| Rendement op eigen vermogen | -29.6% |
| Nettomarge | -12.3% |
| Volgende winstupdate | 06 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
A Piece Of The Puzzle Missing From OrganoClick AB (publ)'s (STO:ORGC) 26% Share Price Climb
Jun 19
Shareholders May Find It Hard To Justify Increasing OrganoClick AB (publ)'s (STO:ORGC) CEO Compensation For Now
May 09Earnings Release: Here's Why Analysts Cut Their OrganoClick AB (publ) (STO:ORGC) Price Target To kr3.00
May 03Sentiment Still Eluding OrganoClick AB (publ) (STO:ORGC)
Mar 25Earnings Update: OrganoClick AB (publ) (STO:ORGC) Just Reported And Analysts Are Trimming Their Forecasts
Feb 18OrganoClick (STO:ORGC) Seems To Use Debt Quite Sensibly
Jan 09Is OrganoClick AB (publ) (STO:ORGC) Potentially Undervalued?
May 11There's No Escaping OrganoClick AB (publ)'s (STO:ORGC) Muted Revenues Despite A 33% Share Price Rise
Apr 18Here's Why OrganoClick (STO:ORGC) Can Afford Some Debt
Jan 25Does OrganoClick (STO:ORGC) Have A Healthy Balance Sheet?
Sep 21OrganoClick AB (publ) (STO:ORGC) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 21Health Check: How Prudently Does OrganoClick (STO:ORGC) Use Debt?
Feb 20Is OrganoClick (STO:ORGC) Weighed On By Its Debt Load?
Apr 20Loss-Making OrganoClick AB (publ) (STO:ORGC) Expected To Breakeven In The Medium-Term
Mar 23Should You Take Comfort From Insider Transactions At OrganoClick AB (publ) (STO:ORGC)?
Feb 12
What Percentage Of OrganoClick AB (publ) (STO:ORGC) Shares Do Insiders Own?
Jan 05Analysts Expect Breakeven For OrganoClick AB (publ) (STO:ORGC) Before Long
Dec 18Calculating The Fair Value Of OrganoClick AB (publ) (STO:ORGC)
Dec 03Opbrengsten en kosten
Hoe OrganoClick geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 138 | -17 | 37 | 7 |
| 31 Mar 24 | 141 | -17 | 37 | 7 |
| 31 Dec 23 | 146 | -16 | 37 | 7 |
| 30 Sep 23 | 140 | -28 | 39 | 7 |
| 30 Jun 23 | 128 | -33 | 41 | 7 |
| 31 Mar 23 | 126 | -40 | 42 | 8 |
| 31 Dec 22 | 115 | -44 | 43 | 8 |
| 30 Sep 22 | 111 | -36 | 42 | 8 |
| 30 Jun 22 | 112 | -35 | 42 | 8 |
| 31 Mar 22 | 113 | -32 | 41 | 7 |
| 31 Dec 21 | 110 | -33 | 40 | 8 |
| 30 Sep 21 | 110 | -31 | 38 | 7 |
| 30 Jun 21 | 108 | -29 | 38 | 7 |
| 31 Mar 21 | 104 | -24 | 34 | 6 |
| 31 Dec 20 | 96 | -24 | 33 | 5 |
| 30 Sep 20 | 93 | -23 | 31 | 5 |
| 30 Jun 20 | 89 | -23 | 30 | 5 |
| 31 Mar 20 | 86 | -23 | 30 | 5 |
| 31 Dec 19 | 85 | -20 | 29 | 4 |
| 30 Sep 19 | 84 | -18 | 29 | 4 |
| 30 Jun 19 | 84 | -18 | 29 | 4 |
| 31 Mar 19 | 82 | -18 | 30 | 4 |
| 31 Dec 18 | 78 | -20 | 31 | 3 |
| 30 Sep 18 | 78 | -23 | 32 | 3 |
| 30 Jun 18 | 78 | -24 | 32 | 4 |
| 31 Mar 18 | 75 | -26 | 31 | 4 |
| 31 Dec 17 | 75 | -28 | 31 | 4 |
| 30 Sep 17 | 69 | -26 | 34 | 3 |
| 30 Jun 17 | 62 | -26 | 36 | 2 |
| 31 Mar 17 | 51 | -28 | 38 | 1 |
| 31 Dec 16 | 40 | -29 | 39 | 0 |
| 30 Sep 16 | 38 | -28 | 37 | 0 |
| 30 Jun 16 | 37 | -25 | 35 | 0 |
| 31 Mar 16 | 33 | -22 | 33 | 0 |
| 31 Dec 15 | 32 | -20 | 31 | 0 |
| 30 Sep 15 | 30 | -17 | 28 | 0 |
| 30 Jun 15 | 27 | -16 | 26 | 0 |
| 31 Mar 15 | 24 | -16 | 26 | 0 |
| 31 Dec 14 | 21 | -16 | 24 | 0 |
| 30 Sep 14 | 20 | -15 | 23 | 0 |
| 31 Dec 13 | 8 | -9 | 15 | 0 |
Kwaliteitswinsten: ORGC is currently unprofitable.
Groeiende winstmarge: ORGC is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ORGC is unprofitable, and losses have increased over the past 5 years at a rate of 5% per year.
Versnelling van de groei: Unable to compare ORGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ORGC is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-6.3%).
Rendement op eigen vermogen
Hoge ROE: ORGC has a negative Return on Equity (-29.57%), as it is currently unprofitable.